Fine Real

Ongoing: active inclusion

S-nummer: S67480 Phase: observational, post-approval
Principal Investigator: prof. dr. Björn Meijers

Title: A non-interventional study providing insights into the use of finerenone in a routine clinical setting.

Purpose and rationale: This international study is a prospective, non-interventional multicenter, single arm study of participant with a diagnosis of CKD associated with T2D who are newly prescribed finerenone. The aim of this study is to provide insights on characteristics and treatment patterns of participant with CKD and T2D treated with finerenone in routine clinical practice.

Primary endpoint: To describe clinical characteristics of and treatment pattern in participants with CKD and T2D treated with finerenone, based on: 1) Clinical characteristics of participants with CKD and T2D 2) Reasons for introducing finerenone 3) Reasons for discontinuation of finerenone 4) Planned and actual duration of treatment with finerenone 5) Planned and actual dosing of finerenone 6) Use of secondary therapies in participants with CKD and T2D.

Medication/treatment: Observation of Finerenone (Kerendia, Non-steroidal MRA) as per local practise. No study drug will be administered in this observational study. Treatment decisions are independent of patient participation in the study and according to clinical practice.

Duration of study: a maximum period of 12 months after start of finerenone or until 30 days after permanent discontinuation of finerenone. (Without any additional study visits.)

Key inclusion criteria:
- Male and female patients over the age of 18
- Diagnosis of CKD associated with T2D
- Treatment according to local marketing authorization, finerenone 20 or 10 mg. Treatment should have been started up to 8 weeks before or after the ICF is signed
- Decision to initiate treatment with finerenone must be made before ICF is signed

Key exclusion criteria:
- Contra-indications according to the local label